Fig. 2
From: Current and future therapies for small cell lung carcinoma
Key pathways in SCLC. The dual inactivation of TP53 and RB1 can promote tumor progression and metastasis, whereas the overexpression of MYC facilitates the acquisition of drug resistance in tumors. Alterations in the Notch pathway promote metastasis and invasion, and the PI3K/Akt/mTOR pathway is associated with tumor formation and chemotherapy resistance. Abbreviations: DLL3, delta-like canonical notch ligand 3; HDAC1/2, histone deacetylases 1 and 2, LSD1/KDM1A, lysine-specific demethylase 1A; mTOR, mammalian target of rapamycin; PI3K, phosphatidylinositol-3-kinase; PIP3, phosphatidylinositol (3,4,5)-trisphosphate; RCOR1/CoREST1, corepressor protein 1; SIRT3, sirtuin 3; TSC, tuberous sclerosis complex; YAP, yes-associated protein